All patients
Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), atezolizumab alone vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 1.02 [0.83; 1.25]
IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
IMvigor-211 (PDL1>1%), 2018 0.87 [0.72; 1.06]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.63; 1.21]
0.90 [0.81 ; 0.99 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 4 0% 2,550 moderate not evaluable deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.64; 1.18]
0.83 [0.73 ; 0.94 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,165 moderate not evaluable progression or deaths (PFS)detailed results IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
IMvigor-211 (PDL1>1%), 2018 0.86 [0.53; 1.39]
IMvigor-211 (PDL1>5%), 2018 1.01 [0.76; 1.35]
0.95 [0.77 ; 1.17 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,790 moderate not evaluable DORdetailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.21 [0.12; 0.37]
IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
IMvigor-211 (PDL1>1%), 2018 0.20 [0.08; 0.50]
IMvigor-211 (PDL1>5%), 2018 0.16 [0.04; 0.55]
0.19 [0.13 ; 0.28 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 4 0% 520 moderate not evaluable objective responses (ORR)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.38 [0.28; 0.53]
IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
IMvigor-211 (PDL1>1%), 2018 0.95 [0.61; 1.49]
IMvigor-211 (PDL1>5%), 2018 1.07 [0.58; 2.00]
0.77 [0.44 ; 1.34 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 4 86% 2,550 moderate not evaluable AE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.14 [0.05; 0.40]
IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
IMvigor-211 (PDL1>5%), 2018 0.67 [0.11; 4.10]
0.29 [0.13 ; 0.67 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 37% 1,872 moderate not evaluable AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.12 [0.08; 0.17]
IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
IMvigor-211 (PDL1>5%), 2018 1.38 [0.81; 2.33]
0.51 [0.12 ; 2.06 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 98% 1,872 moderate not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 1.59 [0.88; 2.87]
IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
IMvigor-211 (PDL1>5%), 2018 0.73 [0.16; 3.34]
1.19 [0.78 ; 1.83 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,872 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.13 [0.08; 0.21]
IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
IMvigor-211 (PDL1>5%), 2018 0.44 [0.20; 0.99]
0.27 [0.12 ; 0.59 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 84% 1,884 moderate not evaluable SAE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.78 [0.59; 1.05]
IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
IMvigor-211 (PDL1>5%), 2018 1.79 [1.05; 3.05]
1.02 [0.70 ; 1.48 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 72% 1,872 moderate not evaluable STRAE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.41 [0.28; 0.60]
IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
IMvigor-211 (PDL1>5%), 2018 0.92 [0.48; 1.80]
0.55 [0.38 ; 0.81 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 57% 1,872 moderate not evaluable TRAE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.04; 0.11]
IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
IMvigor-211 (PDL1>5%), 2018 0.38 [0.19; 0.79]
0.19 [0.07 ; 0.52 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 91% 1,872 moderate not evaluable TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.04 [0.03; 0.06]
IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
IMvigor-211 (PDL1>5%), 2018 0.55 [0.31; 0.99]
0.20 [0.04 ; 0.89 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 98% 1,872 moderate not evaluable TRAE leading to death (grade 5)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.82 [0.18; 3.71]
IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.14; 7.10]
0.61 [0.26 ; 1.41 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,872 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.37 [0.15; 0.92]
0.25 [0.15 ; 0.41 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.02; 0.30]
IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.19; 4.97]
0.30 [0.08 ; 1.11 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 69% 1,872 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.63 [0.18; 2.15]
IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
IMvigor-211 (PDL1>5%), 2018 0.49 [0.04; 5.45]
0.48 [0.24 ; 0.93 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,872 moderate not evaluable Constipation TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.12 [0.01; 2.28]
0.05 [0.01 ; 0.38 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 2.21 [0.20; 24.48]
2.21 [0.20 ; 24.48 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.73 [0.12; 4.41]
IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
IMvigor-211 (PDL1>5%), 2018 2.00 [0.36; 11.15]
0.65 [0.24 ; 1.77 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 35% 1,872 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
IMvigor-211 (PDL1>5%), 2018 0.09 [0.01; 1.75]
0.05 [0.01 ; 0.26 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Nausea TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.27 [0.01; 6.11]
0.27 [0.01 ; 6.11 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.03 [0.00; 0.52]
IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
IMvigor-211 (PDL1>5%), 2018 0.20 [0.04; 0.97]
0.07 [0.02 ; 0.25 ] IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 34% 1,872 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
IMvigor-211 (PDL1>5%), 2018 0.32 [0.03; 3.14]
0.19 [0.04 ; 0.87 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 1.10 [0.02; 55.68]
1.10 [0.02 ; 55.68 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Rash TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 4.43 [0.20; 98.49]
4.43 [0.20 ; 98.49 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
0.08 [0.01 ; 0.58 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.05; 0.13]
0.08 [0.05 ; 0.13 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.51 [0.24; 1.10]
0.51 [0.24 ; 1.10 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.22 [0.09; 0.54]
0.22 [0.09 ; 0.54 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.05 [0.00; 0.92]
0.05 [0.00 ; 0.92 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.54 [0.18; 1.61]
0.54 [0.18 ; 1.61 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.02 [0.00; 0.25]
0.02 [0.00 ; 0.25 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Nausea AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
0.08 [0.01 ; 0.58 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Neutropenia AE (grade 3-4)detailed results Out of scale IMvigor-130 (At-arm B vs Ch-armC), 2020 0.00 [0.00; 0.05]
0.00 [0.00 ; 0.05 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.01 [0.00; 0.10]
0.01 [0.00 ; 0.10 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Vomiting AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.10 [0.01; 0.76]
0.10 [0.01 ; 0.76 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 19:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 361